Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC

Clinical trial NCT06467617 · RECRUITING

Trial details

NCT number: NCT06467617
Sponsor: Beijing Chest Hospital, Capital Medical University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non Small Cell Lung Cancer

Start date: 2024-08-14
Primary completion: 2026-08-01
Enrollment: 35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.